Comparison of efficiency of omega-3 polyunsaturated fatty acids, statins and their combination on lipids parameters, vascular-thrombocyte homeostasis and heart rate variability parameters in patients with type 2 diabetes mellitus and cardiovascular autono

Main Article Content

V.A. Serhiyenko
S. Azhmi
A.A. Serhiyenko


Background. The analysis of combined omega-3 polyunsaturated fatty acids (w-3 PUFAs) and statins prescription to patients with cardiac autonomic neuropathy (CAN) and type 2 diabetes mellitus (T2DM) is of great interest. However existing data about features of their prescription are fragmentary, under discussion and thus require further investigation. Purpose of the study was to compare the influence of w-3 PUFAs, statins and their combination on lipids parameters, vascular-thrombocyte homeostasis and heart rate variability (HRV) parameters in patients with T2DM and CAN. Materials and methods. The study involved 75 patients with T2DM and functional stage of CAN. The concentration of glucose, HbA1c, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), endothelin-1 (ET-1), thromboxane B2 (TXB2), 6-ketoprostoglandine F1a (6-ketoPGF1a) in the blood were determined; atherogenic coefficient (AC) and TXB2/6-ketoPGF1a were calculated. Short time HRV was analyzed using time and spectral parameters. Patients with T2DM and functional stage of CAN were divided into four groups: patients in the 1st group (n = 21) received one capsule/day of w-3 PUFAs in addition to standard treatment; patients in the 2nd group (n = 22) received simvastatin 20 mg/daily; patients of the 3rd group (n = 17) received one capsule of w-3 PUFAs and simvastatin 10 mg/daily; patients of the 4rd group (n = 22) took standard glucose lowering therapy (control group). The study lasted 3 months. Results. Administration of w-3 PUFAs to patients with T2DM and CAN promoted to the statistically significant decrease in TG, AC and increase of HDL-C, but no significant changes of TC and LDL-C was found. Prescription of simvastatin was accompanied by statistically significant decrease in TC, LDL-C, AC, ТХВ2, TXB2/6-ketoPGF1a and increase in HDL-C, ЕТ-1, 6-ketoPGF1a levels; time-domain and spectral parameters of HRV. Combined administration of w-3 PUFAs and simvastatin promoted to the most statistically significant positive changes of lipid profile, endothelial function, ТХВ2,TXB2/6-ketoPGF1a levels, time-domain and spectral parameters of HRV. Conclusions. Obtained results demonstrated that effects of combined simvastatin and omega-3 PUFAs prescription are not connected with diabetes mellitus compensation state and are the results of an direct influence of this pharmacological agents on investigated parameters, that justify the appropriateness of their prescription to patients with T2DM and functional stage of CAN.

Article Details

How to Cite
Serhiyenko, V., S. Azhmi, and A. Serhiyenko. “Comparison of Efficiency of Omega-3 Polyunsaturated Fatty Acids, Statins and Their Combination on Lipids Parameters, Vascular-Thrombocyte Homeostasis and Heart Rate Variability Parameters in Patients With Type 2 Diabetes Mellitus and Cardiovascular Autono”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 5, Oct. 2017, pp. 315-23, doi:10.22141/2224-0721.13.5.2017.110020.
Original Researches


Vinik AI, Erbas T. Diabetic autonomic neuropathy. Handb Clin Neurol. 2013;117(22):279-94. doi: 10.1016/B978-0-444-53491-0.00022-5.

McGuire DK, Marx N, authors. Cardiovascular autonomic neuropathy. In: Diabetes in cardiovascular disease: A companion to braunworld’s heart disease. Amsterdam: Elsevier Saunders; 2015. 361-368pp.

American Diabetes Association. Standards of Medical Care in Diabetes—2017: Summary of Revisions. Diabetes Care 2017 Jan; 40(Suppl 1): S4-S5. doi:10.2337/dc17-S003.

Serhiyenko VA, Serhiyenko AA. Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives? World J Diabetes. 2015 Mar 15; 6(2):245-58. doi: 10.4239/wjd.v6.i2.245.

Serhiyenko VA, Serhiyenko AA. Diabetic cardiovascular autonomic neuropathy. Lviv: Danylo Halytsky Lviv National Medical University; 2016. 268 p. (in Ukrainian).

Sytze Van Dam P, Cotter MA, Bravenboer B, Cameron NE. Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms. Eur J Pharmacol. 2013 Nov 5;719(1-3):180-6. doi: 10.1016/j.ejphar.2013.07.017.

Nikishin AG, Nurbaev TA, Khasanov MS, et al. Possibility of the heart rate variability correction with a high dose of omega-3-polyunsaturated fatty acids in patients with acute myocardial infarction and concomitant type 2 diabetes mellitus. Int J Biomed. 2014; 4(3):138-42.

Goit RK, Paudel BH, Khadka R, Roy RK, Shrewastwa MK. Mild-to-moderate intensity exercise improves cardiac autonomic drive in type 2 diabetes. J Diabetes Investig. 2014 Nov;5(6):722-7. doi: 10.1111/jdi.12238.

Ascaso JF. Advances in cholesterol-lowering interventions. Endocrinol Nutr. 2010 May;57(5):210-9. doi: 10.1016/j.endonu.2010.03.008. (in Spanish).

Serhiyenko VA. Dyslipoproteinemia in diabetes mellitus type 2: basic treatment directions (review of literature and own data). J NAMS Ukraine. 2012;18(2):205-16. (in Ukrainian).

Endo J, Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. J Cardiol. 2016 Jan;67(1):22-7. doi: 10.1016/j.jjcc.2015.08.002.

Pertseva NO, Martsynik EN, Chursinova TV. Features of insulin resistance in patients with long history of type 1 diabetes mellitus, methods of Its correction. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2017;13(1):13-7. doi 10.22141/2224-0721.13.1.2017.96750. (in Russian).

Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management on behalf of The Toronto Consensus panel on diabetic neuropathy. Diabetes Metab Res Rev. 2011 Oct;27(7):639-53. doi: 10.1002/dmrr.1239.

De Pace NL, Mears JP, Yayac M, Colombo J. Cardiac autonomic testing and diagnosing heart disease. “A clinical perspective”. Heart Int. 2014 Jul-Dec; 9(2): 37-44. doi: 10.5301/heartint.5000218.

Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol. 1999 Sep;34(3):912-48. doi: 10.1016/S0735-1097(99)00354-X.

Lapach SN, Chubenko AV, Babich PN. Statistical methods in biomedical research using Excel. Кyiv: Morion; 2001. 320 p. (in Russian).

Serhiyenko VA, Serhiyenko AA, Efimov AS. Long-chain ω-3 polyunsaturated fatty acids: cardiovascular diseases and type 2 diabetes mellitus (review of literature and own data). J NAMS Ukraine. 2011;17(4):353-67. (in Ukrainian).

Serhiyenko VA, Serhiyenko AA, Mankovsky BN. Higher omega-3 polyunsaturated fatty acids, statins, benfotiamine and alpha-lipoic acid in the treatment of cardiac autonomic neuropathy in patients with type 2 diabetes mellitus. J NAMS Ukraine. 2013;19(1):57-64. (in Ukrainian).

Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Omega-3 polyunsaturated fatty acids in the treatment of diabetic cardiovascular autonomic neuropathy: A review. In: Moore SJ, editors. Omega-3: Dietary sources, biochemistry and impact on human health. New York: Nova Science Publishers; 2017. 79-154pp. 

Pernow J, Shemyakin A, Bohm F. New perspectives onendothelin-1 in atherosclerosis and diabetes mellitus. Life Sci. 2012 Oct 15;91(13-14):507-16. doi: 10.1016/j.lfs.2012.03.029.

Sánchez A, Martínez P, Muñoz P, et al. Endothelin-1 contributes to endothelial dysfunction and enhanced vasoconstriction through augmented superoxide production in penile arteries from insulin-resistant obese rats: role of ETA and ETB receptors. Br J Pharmacol. 2014 Dec; 171(24): 5682-95. doi: 10.1111/bph.12870.

Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;2011:742719. doi: 10.1155/2011/742719.

Suslova TE, Sitozhevskii AV, Ogurkova ON, et al. Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation. Front Physiol. 2015 Jan 5;5:501. doi: 10.3389/fphys.2014.00501.